Acorda regains rights to Fampyra after Biogen terminates license agreement

Acorda Therapeutics (ACOR) announced it will regain global commercialization rights to Fampyra following a decision by Biogen (BIIB) to terminate the license and collaboration agreement between the companies, effective January 1, 2025. Fampyra is indicated in the European Union and other territories throughout the world for the improvement of walking in adults with multiple sclerosis, or MS, with walking disability. Acorda markets the medication as Ampyra in the United States. Acorda and Biogen are working together toward a transition for Acorda to commercialize and supply Fampyra for the great majority of people with MS outside the United States currently being served. Acorda plans to assume commercialization responsibilities as soon as possible during 2024 as marketing authorization transfers and distribution arrangements are finalized for each territory.